Abcellera Biologics Stock Today
| ABCL Stock | USD 3.23 0.03 0.94% |
Performance6 of 100
| Odds Of DistressLess than 22
|
Abcellera Biologics is selling for 3.23 as of the 30th of January 2025. This is a 0.94 percent increase since the beginning of the trading day. The stock's lowest day price was 3.19. Abcellera Biologics has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 12th of March 2023 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of December 2020 | Category Healthcare | Classification Health Care |
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. The company has 295.37 M outstanding shares of which 17.26 M shares are presently shorted by private and institutional investors with about 5.37 trading days to cover. More on Abcellera Biologics
Moving against Abcellera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Abcellera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Carl Hansen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAbcellera Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Abcellera Biologics' financial leverage. It provides some insight into what part of Abcellera Biologics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abcellera Biologics (ABCL) is traded on NASDAQ Exchange in USA. It is located in 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 and employs 586 people. Abcellera Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 945.17 M. Abcellera Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 295.37 M outstanding shares of which 17.26 M shares are presently shorted by private and institutional investors with about 5.37 trading days to cover.
Abcellera Biologics currently holds about 868.21 M in cash with (43.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04.
Check Abcellera Biologics Probability Of Bankruptcy
Ownership AllocationAbcellera Biologics holds a total of 295.37 Million outstanding shares. Abcellera Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Abcellera Ownership Details
Abcellera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Federated Hermes Inc | 2024-09-30 | 2.3 M | |
| Two Sigma Advisers, Llc | 2024-09-30 | 2.2 M | |
| Guardian Capital Advisors Lp | 2024-09-30 | 1.8 M | |
| Citadel Advisors Llc | 2024-09-30 | 1.5 M | |
| Novo A/s | 2024-09-30 | 1.1 M | |
| Lazard Asset Management Llc | 2024-09-30 | 1.1 M | |
| Norges Bank | 2024-06-30 | 922.2 K | |
| Opaleye Management Inc | 2024-09-30 | 800 K | |
| Millennium Management Llc | 2024-09-30 | 753.9 K | |
| Baker Bros Advisors Lp | 2024-09-30 | 27.5 M | |
| Baillie Gifford & Co Limited. | 2024-09-30 | 12.9 M |
Abcellera Biologics Historical Income Statement
Abcellera Stock Against Markets
Abcellera Biologics Corporate Management
| Andy Clark | Head Assurance | Profile | |
| Veronique Lecault | COO Director | Profile | |
| Bo Barnhart | Scientific Director | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| EdD CEC | Senior Development | Profile | |
| Paul Colussi | Site Technologies | Profile | |
| JD Esq | Chief Officer | Profile |
Already Invested in Abcellera Biologics?
The danger of trading Abcellera Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abcellera Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abcellera Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abcellera Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.